

# Hyaluronan-Cyclodextrin Conjugates as Doxorubicin Delivery Systems

Noemi Bognanni<sup>1</sup>, Maurizio Viale<sup>2</sup>, Luana La Piana<sup>1</sup>, Simone Strano<sup>1</sup>, Rosaria Gangemi<sup>2</sup>,  
Cinzia Lombardo<sup>3</sup>, Maria Teresa Cambria<sup>3</sup> and Graziella Vecchio<sup>1,\*</sup>

<sup>1</sup> Dipartimento di Scienze Chimiche, Università degli Studi di Catania, Viale A. Doria 6, 95125 Catania, Italy

<sup>2</sup> UOC Bioterapie, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genova, Italy

<sup>3</sup> Dipartimento di Scienze Biomediche e Biotecnologiche, Sezione di Biochimica Medica, Università degli Studi di Catania, Via S. Sofia 97, 95125 Catania, Italy

\* Correspondence: gr.vecchio@unict.it




Figure S1.  $^1\text{H}$  NMR spectrum of HAL $\beta$ CyD ( $\text{D}_2\text{O}$ , 500 MHz)




Figure S2.  $^1\text{H}$  NMR spectrum of HAH $\beta$ CyD ( $\text{D}_2\text{O}$ , 500 MHz)





Figure S3. UV-Vis spectra of saturated solution of DOXO in the presence of an increasing concentration of the polymer: HAL $\beta$ CyD (Left) and HAH $\beta$ CyD (right) at pH 7.4, phosphate buffer



**Figure S4.** Graphs represent the mean dose-response curves of SK-N-SH (top) and SK-N-SH-PMA (bottom) cells treated with DOXO or DOXO/HALβCyD 8/1, DOXO/HALβCyD 8/1, DOXO/HALβCyD 16/1, and DOXO/HALβCyD 16/1 complexes.